Drug Trial Radar · NCT07095855
A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB
Last checked: Nov 19, 2026Latest source record: Aug 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,300
Planned (sponsor's estimate)
Start
Aug 2025
Primary completion
Jan 2028
Study completion Jan 2030
Sponsor
- Lead sponsor
- Shanghai Zhimeng Biopharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is divided into two parts. Part A is a multicenter, randomized, double-blind, placebo controlled phase Ill clinical trial, designed to evaluate the efficacy and safety of ZM-H1505R in combination with NAs versus NAs monotherapy with HBV DNA ≥ 50 IU/mL and are HBeAg positive who have received NAs monotherapy for at least 12months.Part B is an open-label extension and follow-up period designed to evaluate the long-term safety and efficacy of ZM-H1505R in combination with NAs.
Conditions
- Chronic Hepatitis B
Interventions
ZM-H1505R 100mgDrug
ZM-H1505R(100mg,QD) will be used in Part A double-blind treatment period for 48 weeks and Part B open-label extension period 144 weeks.
ZM-H1505R PlaceboOther
ZM-H1505R Placebo(100mg,QD) will be used in Part A double-blind treatment period for 48 weeks.
NAs ("Entecavir"or"Tenofovir"or"Tenofovir alafenamide"or"TMF") treatmentsCombination product
All eligible subjects will be use NAs ("Entecavir"or"Tenofovir"or"Tenofovir alafenamide"or"TMF") treatments during the study for 148 weeks, including Part A and Part B. Subjects will continue to use the NAs as combination therapy before enrollment, the dosage will not be adjusted during the study. Subjects use in accordance with medical advice andinstructions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects achieves complete virologic response (CVR) at week 48 of treatment.Time frame: 48 week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Hospital of Jilin University
Changchun, Jilin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.